Rapport Therapeutics and Tenacia Biotechnology Announce Collaboration to Develop RAP-219 in Greater China
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotechnology company focused on precision medicines for neurological and psychiatric disorders, and Tenacia Biotechnology, a biopharmaceutical company focused on therapies for neurological disorders, announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including mainland China, Hong Kong, Macau and Taiwan. RAP-219 is a […]